← back to search

Sigrid Hatse

VIB-KU Leuven Center for Cancer Biology · BE
Area of research
Oncology · Virology
Research interest
Research interests include HIV Research and Treatment, Chemokine receptors and signaling, Cancer Immunotherapy and Biomarkers, and Immune Cell Function and Interaction.
h-index
43
citations
5,975
works
213
NIH funding
primary concept
email

Recent publications

Identifying pre-treatment risk factors for cancer-related cognitive decline in patients with breast cancer
The Breast 2026cited by 0position: middledoi
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy
Immunity 2024cited by 94position: middledoi
Rapid autopsies to enhance metastatic research: the UPTIDER post-mortem tissue donation program
npj Breast Cancer 2024cited by 17position: middledoi
A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling
Nature Cancer 2023cited by 139position: middledoi
Trial watch: chemotherapy-induced immunogenic cell death in oncology
OncoImmunology 2023cited by 81position: middledoi
Pregnancy After Breast Cancer in Young <i>BRCA </i>Carriers
JAMA 2023cited by 53position: middledoi
Cancer and Aging: Two Tightly Interconnected Biological Processes
Cancers 2021cited by 232position: lastdoi
Is cancer biology different in older patients?
The Lancet Healthy Longevity 2021cited by 157position: middledoi
Neuroinflammation and Its Association with Cognition, Neuronal Markers and Peripheral Inflammation after Chemotherapy for Breast Cancer
Cancers 2021cited by 66position: middledoi
Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element
The American Journal of Human Genetics 2021cited by 12position: middledoi
Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk
JNCI Journal of the National Cancer Institute 2020cited by 73position: middledoi
Computerised scoring protocol for identification and quantification of different immune cell populations in breast tumour regions by the use of QuPath software
Histopathology 2020cited by 46position: middledoi
Age‐related remodelling of the blood immunological portrait and the local tumor immune response in patients with luminal breast cancer
Clinical & Translational Immunology 2020cited by 38position: lastdoi
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters
Oncotarget 2016cited by 52position: middledoi
rs2735383, located at a microRNA binding site in the 3’UTR of NBS1, is not associated with breast cancer risk
Scientific Reports 2016cited by 4position: middledoi
Clinical and genetic risk factors for epirubicin-induced cardiac toxicity in early breast cancer patients
Breast Cancer Research and Treatment 2015cited by 75position: middledoi
Biological ageing and frailty markers in breast cancer patients
Aging 2015cited by 60position: middledoi
Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Breast Cancer Research 2015cited by 24position: middledoi
Circulating MicroRNAs as Easy-to-Measure Aging Biomarkers in Older Breast Cancer Patients: Correlation with Chronological Age but Not with Fitness/Frailty Status
PLoS ONE 2014cited by 67position: firstdoi
Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast
PLoS Genetics 2014cited by 48position: middledoi
Evaluating the physiological reserves of older patients with cancer: The value of potential biomarkers of aging?
Journal of Geriatric Oncology 2013cited by 81position: middledoi
Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
Annals of Oncology 2013cited by 74position: middledoi
Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency
Carcinogenesis 2012cited by 106position: firstdoi
The role of genetic breast cancer susceptibility variants as prognostic factors
Human Molecular Genetics 2012cited by 84position: middledoi
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2
PLoS ONE 2012cited by 13position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Hans Wildiers · CHU Dinant Godinne UCL Namur10 papers (2013–2021)Patrick Neven · European Organisation for Research and Treatment of Cancer6 papers (2012–2020)Barbara Brouwers · KU Leuven6 papers (2012–2016)Annouschka Laenen · KU Leuven5 papers (2012–2020)Ann Smeets · Universitair Ziekenhuis Leuven4 papers (2015–2021)Patrick Schöffski · Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori4 papers (2013–2016)Bruna Dalmasso · KU Leuven4 papers (2014–2020)Cindy Kenis · Twitter (United States)4 papers (2014–2020)Robert Paridaens · Universitair Ziekenhuis Leuven3 papers (2012–2015)Giuseppe Floris · Twitter (United States)3 papers (2020–2021)Diether Lambrechts · Center for Human Genetics3 papers (2012–2015)Lieze Berben · KU Leuven3 papers (2020–2021)Lissandra Dal Lago · University of Colorado Denver2 papers (2013–2016)Asier Antoranz · VIB-KU Leuven Center for Cancer Biology2 papers (2020–2020)Oliver Bechter · Universitair Ziekenhuis Leuven2 papers (2016–2021)Christof Vulsteke · The European Academy of Gynaecological Surgery2 papers (2013–2015)Anne-Sophie Dieudonné · KU Leuven2 papers (2012–2015)Gwen Schroyen · KU Leuven2 papers (2021–2026)Graham Pawelec · Twitter (United States)2 papers (2013–2016)Sabine Deprez · Cancer Institute (WIA)2 papers (2021–2026)